CASI Pharmaceuticals (CASIF) Non-Current Assets (2021 - 2025)

CASI Pharmaceuticals has reported Non-Current Assets for 5 years, with the latest figure at $12.2 million in Q4 2025.

• For the quarter ending Q4 2025, Non-Current Assets fell 13.51% year-over-year to $12.2 million; the trailing twelve-month figure through Dec 2025 stood at -$27.1 billion (up 71.87% YoY), and the FY2025 full-year result was $12.2 million, down 13.51% from the prior year.
• Non-Current Assets for Q4 2025 stood at $12.2 million, down from $12.5 million in the prior quarter.
• The five-year high for Non-Current Assets was $76.3 million in Q4 2021, with the low at -$61.0 billion in Q2 2023.
• Historically, Non-Current Assets has averaged -$16.8 billion across 5 years, with a median of $12.5 million in 2025.
• Annual changes were most pronounced in 2023 — Non-Current Assets sank 259925.22% — and 2025, when it soared 100.04%.
• CASI Pharmaceuticals' Non-Current Assets stood at $76.3 million in 2021, then slumped by 70.11% to $22.8 million in 2022, then slumped by 259925.22% to -$59.3 billion in 2023, then surged by 100.02% to $14.1 million in 2024, then retreated by 13.51% to $12.2 million in 2025.
• The last three Non-Current Assets figures came in at $12.2 million (Q4 2025), $12.5 million (Q3 2025), and $13.0 million (Q2 2025), per Business Quant data.